Mary Pao

Mary Pao is Chief Medical Officer at ANI Pharmaceuticals, where she leads medical and scientific strategy across multiple autoimmune disease states. ANI Pharmaceuticals is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products. Prior to ANI Pharmaceuticals, Pao was managing partner and head of clinical affairs at Real Chemistry, a global healthcare consultancy, where she led medical strategy for a commercialization service platform designed to optimize launch success. In addition to working at Real Chemistry, Pao was a founding partner of Arcus Medica, a consulting company specializing in launch strategy and execution. She previously served at GSK as a global and a North American medical affairs oncology lead and at Genentech as both clinical lead for the B-Cell Diagnostics Team and Rituxan Medical Affairs lead. She has over 30 years of basic science and industry experience developing novel therapies and executing launch strategies, working with medical affairs, clinical development, and commercial teams. Her disease state expertise includes hematology, oncology, rare disease, nephrology, neurology, and autoimmune disease. Pao earned degrees from Princeton University in molecular biology and public and international affairs, and her MD and PhD from New York University School of Medicine. She completed her residency training at Harvard School of Medicine and her hematology and oncology fellowship training at Cornell Weill Department of Medicine and Memorial Sloan-Kettering Cancer Center.